Johnson & Johnson announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for its dual‑action tablet AKEEGA, a combination of niraparib and abiraterone acetate, for the treatment of metastatic hormone‑sensitive prostate cancer in patients with BRCA1/2 mutations.
The CHMP recommendation is grounded in the Phase 3 AMPLITUDE study, which demonstrated a median radiographic progression‑free survival that was not reached versus 26 months in the control arm for the BRCA‑mutated subgroup. The study also reported a 48 % reduction in the risk of radiographic progression or death in this subgroup, confirming the clinical benefit of the combination in a population that historically has a more aggressive disease course.
The approval expands AKEEGA’s indication from metastatic castration‑resistant prostate cancer to the earlier metastatic hormone‑sensitive setting, opening a larger addressable market. Analysts estimate the BRCA‑positive prostate cancer segment could generate $5 billion or more in annual sales, and the drug is expected to contribute significantly to J&J’s oncology revenue, helping to offset the impending revenue cliff from Stelara’s patent expiration and supporting the company’s goal of becoming the number one oncology player with $50 billion in sales by decade‑end.
In the competitive landscape, AKEEGA positions J&J against other precision‑medicine oncology players such as Roche’s PARP inhibitor and Pfizer’s combination therapies. The dual‑action mechanism—combining a PARP inhibitor with an androgen‑deprivation agent—offers a unique therapeutic advantage for BRCA‑mutated patients, potentially capturing market share in a niche that is currently underserved by biomarker‑selected options.
Senior Director Henar Hevia highlighted the unmet need for earlier intervention in BRCA‑positive metastatic prostate cancer, noting that AKEEGA “offers a targeted treatment strategy with the potential to address this urgent medical need earlier in the metastatic pathway.” The company expects the EMA’s positive opinion to accelerate its launch plans in the European Economic Area, with final European Commission approval anticipated within the next 90 days and a market launch slated for the first quarter of 2027.
The positive opinion also signals regulatory confidence in the safety and efficacy profile of the combination, reinforcing J&J’s broader oncology strategy that emphasizes precision medicine and high‑margin assets. The company’s oncology portfolio, which includes Darzalex and Carvykti, is now poised to capture a growing share of the biomarker‑selected prostate cancer market, aligning with its long‑term revenue and margin targets.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.